1201323-97-8

Basic information

• Product Name: 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine
• CAS NO: 1201323-97-8
• Molecular Weight: 268.25
• Mol File: 1201323-97-8.mol

Chemical Properties

• Boiling Point: 443.3±45.0 °C(Predicted)
• Density: 1.51±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine(1201323-97-8)
• EPA Substance Registry System: 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine(1201323-97-8)

Safety Data

• Hazardous Substances Data: 1201323-97-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine is used as a β-Amyloid PET (Positron Emission Tomography) ligand for the detection and monitoring of β-amyloid plaques in the brain. The compound exhibits high binding potency with an IC50 of 10.5 nM, making it a valuable tool in the early diagnosis and assessment of neurodegenerative diseases such as Alzheimer's.
In the field of medical research, 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine serves as a crucial diagnostic agent, enabling the visualization of β-amyloid plaques in the brain. This information is vital for understanding the progression of Alzheimer's disease and evaluating the effectiveness of potential treatments. The high binding affinity of 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine to β-amyloid plaques allows for accurate and sensitive detection, which is essential for guiding therapeutic interventions and improving patient outcomes.
Furthermore, the compound's unique chemical properties and structure may also make it a candidate for further research into the development of novel therapeutic agents targeting neurodegenerative diseases. By understanding the interactions between 5-Fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-oxazolo[5,4-b]pyridine and β-amyloid plaques, scientists can gain insights into the molecular mechanisms underlying Alzheimer's and potentially develop new strategies for treatment.

Upstream product

• 1201324-19-7 C₉H₇ClN₂O 
• 108118-69-0 2,6-difluoropyridin-3-ylamine 
• 934568-20-4 1-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid 
• 517918-95-5 1H-pyrrolo[2,3-b]pyridine-5-carbonitrile 
• 517918-96-6 1-methyl-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile 
• 1201324-20-0 1-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (2,6-difluoro-pyridin-3-yl)-amide 

Relevant articles and documents

Synthesis and evaluation of 5-fluoro-2-aryloxazolo[5,4- b ]pyridines as β-amyloid PET ligands and identification of MK-3328

5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential 18F containing β-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human β-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of β-amyloid plaque load.

NOVEL SUBSTITUTED AZABENZOXAZOLES

The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the